Solventum Corporation v. Wound Healing Technologies, LLC

Solventum Corporation, a global healthcare company recently spun off from 3M in April 2024, has initiated an Inter Partes Review (IPR) against Wound Healing Technologies, LLC. Solventum is an operating company with a broad portfolio including advanced wound care and negative pressure wound therapy (NPWT) products. Wound Healing Technologies, LLC (WHT) is also an operating company specializing in negative pressure wound therapy products and services, primarily serving nursing homes with its Tzoar 207 NPWT System.

The subject of this IPR is U.S. Patent 10,639,404, titled "Wound dressing," which WHT owns. This patent broadly describes apparatus and methods for wound dressings, particularly those used in negative pressure wound therapy (NPT). The alleged invention combines conventional NPT components, such as a drain and a fluid-absorbing layer, with a vapor sealant sheet that specifically incorporates a hydrocolloid material to purportedly simplify wound preparation and enhance sealing. Solventum, as the Petitioner, is challenging the patentability of all 13 claims of the '404 patent, arguing they are unpatentable as obvious based on prior art.

This case, IPR2025-01042, is being heard by the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office. The IPR was filed on June 13, 2025, and has since been instituted, meaning the PTAB found a reasonable likelihood that Solventum would prevail in its challenge to at least one claim. The PTAB provides an administrative forum for challenging patent validity, often in parallel with district court litigation. Indeed, the '404 patent is also asserted by Wound Healing Technologies Corp. in a co-pending patent infringement lawsuit against Solventum Corporation in the Western District of Texas (Case # 6:24-cv-00589-RP), filed on November 15, 2024. This IPR is notable as it represents a common defensive strategy by an accused infringer to invalidate asserted patents in a specialized and competitive healthcare market like wound care, where Solventum is a significant player with its own extensive intellectual property portfolio.

The patent infringement litigation involving the parties Solventum Corporation and Wound Healing Technologies, LLC centers around U.S. Patent No. 10,639,404. While the provided case is an Inter Partes Review (IPR) at the Patent Trial and Appeal Board (PTAB), IPR2025-01042, this IPR is a parallel proceeding to a related district court patent infringement lawsuit.

Here are the key legal developments in chronological order:

District Court Patent Infringement Litigation:

• 2024-11-15 – Complaint Filed: Wound Healing Technologies Corp. (as Plaintiff) filed a patent infringement lawsuit against Solventum Corporation (as Defendant) in the U.S. District Court for the Western District of Texas, Case No. 6:24-cv-00589. The nature of the suit is listed as "Property Rights - Patent" under cause 35:271 Patent Infringement, indicating it involves alleged infringement of a patent. The assigned judge for the case is Robert Pitman.

Parallel PTAB IPR Proceeding:

• 2025-06-13 – IPR Petition Filed: Solventum Corporation, the defendant in the district court litigation, filed a Petition for Inter Partes Review (IPR) against U.S. Patent No. 10,639,404 at the PTAB, initiating case IPR2025-01042. Solventum, as the Petitioner, requested the cancellation of claims 1-13 of the '404 patent, asserting they are unpatentable. The primary ground for unpatentability argued was obviousness over a combination of prior art references, specifically Argenta in view of Hu, for claims 1-7, 11, and 13.

Subsequent IPR Developments:

• 2025-12-13 – IPR Instituted (Estimated): While a precise institution date for IPR2025-01042 is not explicitly available in the provided snippets, IPRs typically receive an institution decision within six months of the petition filing. Given the filing date of June 13, 2025, the institution decision would have occurred around December 13, 2025. The case status provided in the prompt confirms the IPR has been "Instituted," meaning the PTAB decided to proceed with a review of the challenged claims.

Effect of IPR on Litigation (General Context):

It is common for district court litigation to be stayed pending the outcome of an IPR, particularly after institution, to conserve judicial resources and allow the PTAB to first address the patentability of the challenged claims. However, specific information regarding a motion to stay or the status of such a motion in 6:24-cv-00589 is not available in the provided search results.

Current Posture:

• District Court Case (6:24-cv-00589): The district court case, Wound Healing Technologies Corp. v. Solventum Corporation et al., filed on November 15, 2024, is currently open and pending in the Western District of Texas.
• PTAB IPR (IPR2025-01042): The IPR has been instituted and is pending before the PTAB. A final written decision in an IPR is generally due within one year of institution, which would be around December 2026 for IPR2025-01042.

Note on Recent USPTO Policy Changes (General Context):

It is important to note that around the time of institution for IPR2025-01042, the USPTO implemented significant policy changes concerning IPRs. Effective October 20, 2025, the Director of the USPTO began personally determining whether to institute IPR and Post-Grant Review (PGR) proceedings, moving away from prior practices where panels of Administrative Patent Judges made these decisions. These changes were intended to improve efficiency, consistency, and adherence to statutory requirements. Additionally, proposed rules were announced on October 17, 2025, aiming to limit IPR proceedings for claims previously challenged in litigation and to potentially bar institution if a parallel district court case is likely to reach a validity decision first, thereby creating a "race to judgment." While these policy changes were in effect around the institution of IPR2025-01042, there is no specific information in the provided snippets on how they specifically impacted the institution decision for this particular IPR.

Counsel for Solventum Corporation in IPR2025-01042

As of the latest available information, the counsel of record representing Solventum Corporation (Petitioner) in IPR2025-01042 has not been explicitly identified in the provided search results. The available docket information primarily pertains to the Patent Owner, Wound Healing Technologies, LLC.

Wound Healing Technologies, LLC, the Patent Owner, has Joel Weiss (Reg. No. 44,398) as lead counsel and Edward M. Arons (Reg. No. 44,511) as back-up counsel. They are associated with the firm Weiss Arons, and their email addresses are jweiss@weissarons.com and earons@weissarons.com, respectively.

Solventum Corporation itself has an in-house intellectual property team, with Sandra Nowak serving as Chief Intellectual Property Counsel. Her role involves leading a global team responsible for creating, defending, enforcing, and protecting Solventum's intellectual property. However, specific outside counsel representing Solventum in this particular IPR has not been identified in the provided documents.

In IPR2025-01042, Wound Healing Technologies Corp. (WHT) is represented by Joel Weiss as lead counsel and Edward M. Arons as back-up counsel. They are affiliated with the firm Weiss Arons.

Their details are as follows:

• Joel Weiss

  • Role: Lead Counsel
  • Firm: Weiss Arons
  • Office Location: Not specified in the IPR documents, but the firm's contact information for service lists an 845 area code, which typically covers parts of New York.
  • Note: Mr. Weiss has appeared as counsel for Wound Healing Technologies Corp. in the co-pending district court case, 6:24-cv-00589-RP, in the Western District of Texas.

• Edward M. Arons

  • Role: Back-up Counsel
  • Firm: Weiss Arons
  • Office Location: Not specified in the IPR documents, but the firm's contact information for service lists an 845 area code, which typically covers parts of New York.

An attorney named Ariel Reinitz was initially listed as back-up counsel for WHT but was subsequently removed at WHT's request. Mr. Reinitz was affiliated with Bochner PLLC.